Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. High-Mobility Group Box 1 (HMGB1) Is Elevated Systemically in Persons with Acute or Chronic Traumatic Spinal Cord Injury

High-Mobility Group Box 1 (HMGB1) Is Elevated Systemically in Persons with Acute or Chronic Traumatic Spinal Cord Injury

JOURNAL OF NEUROTRAUMA, 2017 · DOI: 10.1089/neu.2016.4596 · Published: February 1, 2017

Spinal Cord InjuryGeneticsBioinformatics

Simple Explanation

This study investigates HMGB1, a protein that promotes inflammation, in patients with spinal cord injuries (SCI). HMGB1 is found to be elevated in preclinical models. The research measures HMGB1 levels in the plasma of adults with acute (within 1 week post-SCI) or chronic (1+ year post-SCI) injuries, comparing them to uninjured individuals. The data suggests that HMGB1 could be an early and persistent signal causing inflammation in SCI patients.

Study Duration
Not specified
Participants
16 acute SCI, 47 chronic SCI, 51 uninjured
Evidence Level
Not specified

Key Findings

  • 1
    HMGB1 levels are significantly elevated in individuals with acute SCI within 0-3 days and 4-7 days post-injury, compared to uninjured controls.
  • 2
    Individuals with chronic SCI also showed significantly elevated HMGB1 levels compared to uninjured persons.
  • 3
    In acute SCI, HMGB1 levels tend to be higher in participants who did not survive acute hospitalization.

Research Summary

The study found that HMGB1 is elevated systemically in persons with acute or chronic traumatic SCI. HMGB1 levels in acute SCI were significantly higher than in uninjured persons and more than two-fold higher than in persons with chronic SCI. HMGB1 levels were elevated independent of neurological completeness or injury level in acute SCI.

Practical Implications

Therapeutic Target

HMGB1 is proposed as a therapeutic target in acute SCI, as anti-HMGB1 therapies have shown promise in pre-clinical studies.

Biomarker Potential

HMGB1 can serve as a biomarker to assess the severity and prognosis of SCI, aiding in the development of personalized treatment strategies.

Inflammation Management

Targeting HMGB1 might help manage the chronic inflammation associated with SCI, potentially reducing secondary medical complications.

Study Limitations

  • 1
    Relatively small number of participants with acute SCI.
  • 2
    HMGB1 was measured in plasma and not cerebrospinal fluid (CSF).
  • 3
    Observations made from separate cohorts of persons with acute or chronic SCI.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury